284 related articles for article (PubMed ID: 19630716)
21. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.
Comai S; Cavalletto L; Chemello L; Bernardinello E; Ragazzi E; Costa CV; Bertazzo A
Pharmacol Res; 2011 Jan; 63(1):85-92. PubMed ID: 20940053
[TBL] [Abstract][Full Text] [Related]
22. Is the interferon-α-triggered depressive episode a self-limited kind of depression? Four cases of persistent affective symptoms after antiviral treatment in HCV-infected individuals.
Galvão-de Almeida A; Quarantini LC; Batista-Neves S; Lyra AC; Paraná R; de Oliveira IR; Miranda-Scippa A; Guindalini C
World J Biol Psychiatry; 2010 Oct; 11(7):914-8. PubMed ID: 20642400
[TBL] [Abstract][Full Text] [Related]
23. DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN.
Vabo IL; Ferreira LE; Pace FH
Arq Gastroenterol; 2016; 53(1):20-4. PubMed ID: 27281500
[TBL] [Abstract][Full Text] [Related]
24. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents.
Al Ali J; Owayed S; Al-Qabandi W; Husain K; Hasan F
Ann Hepatol; 2010; 9(2):156-60. PubMed ID: 20526008
[TBL] [Abstract][Full Text] [Related]
25. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
26. Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
Leung Y; Urbanski SJ; Schindel L; Myers RP
Can J Gastroenterol; 2006 Oct; 20(10):661-3. PubMed ID: 17066158
[TBL] [Abstract][Full Text] [Related]
27. Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals.
Sockalingam S; Sheehan K; Feld JJ; Shah H
Am J Psychiatry; 2015 Jun; 172(6):512-6. PubMed ID: 26029803
[No Abstract] [Full Text] [Related]
28. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.
Druyts E; Thorlund K; Wu P; Kanters S; Yaya S; Cooper CL; Mills EJ
Clin Infect Dis; 2013 Apr; 56(7):961-7. PubMed ID: 23243171
[TBL] [Abstract][Full Text] [Related]
30. Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study.
Loftis JM; Patterson AL; Wilhelm CJ; McNett H; Morasco BJ; Huckans M; Morgan T; Saperstein S; Asghar A; Hauser P
J Psychosom Res; 2013 Jan; 74(1):57-63. PubMed ID: 23272989
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment.
Masip M; Tuneu L; Pagès N; Torras X; Gallego A; Guardiola JM; Faus MJ; Mangues MA
Int J Clin Pharm; 2015 Dec; 37(6):1143-51. PubMed ID: 26267215
[TBL] [Abstract][Full Text] [Related]
32. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
[TBL] [Abstract][Full Text] [Related]
33. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.
Fumaz CR; Muñoz-Moreno JA; Ballesteros AL; Paredes R; Ferrer MJ; Salas A; Fuster D; Masmitjà E; Pérez-Alvarez N; Gómez G; Tural C; Clotet B
AIDS Care; 2007 Jan; 19(1):138-45. PubMed ID: 17129869
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan.
Aziz H; Gil ML; Waheed Y; Adeeb U; Raza A; Bilal I; Athar MA
Infect Genet Evol; 2011 Apr; 11(3):640-5. PubMed ID: 21316487
[TBL] [Abstract][Full Text] [Related]
35. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C.
Schäfer M; Boetsch T; Laakmann G
Addiction; 2000 Jul; 95(7):1101-4. PubMed ID: 10962774
[TBL] [Abstract][Full Text] [Related]
36. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A
J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
[TBL] [Abstract][Full Text] [Related]
37. Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study.
Lang JP; Melin P; Ouzan D; Rotily M; Fontanges T; Marcellin P; Chousterman M; Cacoub P;
Antivir Ther; 2010; 15(4):599-606. PubMed ID: 20587853
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
[TBL] [Abstract][Full Text] [Related]
39. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance.
Mauss S; Berger F; Goelz J; Jacob B; Schmutz G
Hepatology; 2004 Jul; 40(1):120-4. PubMed ID: 15239094
[TBL] [Abstract][Full Text] [Related]
40. Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial.
Suzuki H; Takagi H; Sohara N; Kanda D; Kakizaki S; Sato K; Mori M;
World J Gastroenterol; 2006 Feb; 12(8):1265-9. PubMed ID: 16534882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
